- Home
- CHPT vs ATXS Comparison
CHPT vs ATXS Comparison
Compare CHPT & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- ATXS
- Stock Information
- Founded
- CHPT 2007
- ATXS 2008
- Country
- CHPT United States
- ATXS United States
- Employees
- CHPT N/A
- ATXS N/A
- Industry
- CHPT Industrial Specialties
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- ATXS Health Care
- Exchange
- CHPT Nasdaq
- ATXS Nasdaq
- Market Cap
- CHPT 468.9M
- ATXS 401.2M
- IPO Year
- CHPT N/A
- ATXS 2015
- Fundamental
- Price
- CHPT $0.76
- ATXS $6.81
- Analyst Decision
- CHPT Hold
- ATXS Strong Buy
- Analyst Count
- CHPT 13
- ATXS 6
- Target Price
- CHPT $2.46
- ATXS $25.67
- AVG Volume (30 Days)
- CHPT 33.1M
- ATXS 244.9K
- Earning Date
- CHPT 03-04-2025
- ATXS 03-03-2025
- Dividend Yield
- CHPT N/A
- ATXS N/A
- EPS Growth
- CHPT N/A
- ATXS N/A
- EPS
- CHPT N/A
- ATXS N/A
- Revenue
- CHPT $431,026,000.00
- ATXS N/A
- Revenue This Year
- CHPT N/A
- ATXS N/A
- Revenue Next Year
- CHPT $13.02
- ATXS N/A
- P/E Ratio
- CHPT N/A
- ATXS N/A
- Revenue Growth
- CHPT N/A
- ATXS N/A
- 52 Week Low
- CHPT $0.66
- ATXS $6.64
- 52 Week High
- CHPT $2.44
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- CHPT 35.80
- ATXS 31.94
- Support Level
- CHPT $0.66
- ATXS $6.77
- Resistance Level
- CHPT $0.86
- ATXS $7.30
- Average True Range (ATR)
- CHPT 0.07
- ATXS 0.30
- MACD
- CHPT 0.00
- ATXS 0.02
- Stochastic Oscillator
- CHPT 31.37
- ATXS 14.66
About CHPT ChargePoint Holdings Inc.
ChargePoint designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.